Alberto Puccini
YOU?
Author Swipe
View article: Fertility preservation practices and gastrointestinal oncologist in Europe: a pan-European study
Fertility preservation practices and gastrointestinal oncologist in Europe: a pan-European study Open
Introduction The rising incidence of early-onset gastrointestinal (GI) cancer has made the impact of treatments on fertility of high significance. While there is abundant evidence on oncofertility outcomes in breast cancer and hematologica…
View article: Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life Open
The treatment of locally advanced rectal cancer (LARC) has undergone a significant evolution in recent years, shifting toward more selective strategies that balance oncological outcomes with quality of life (QoL) preservation. Total neoadj…
View article: Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study
Research training, barriers, and career development needs of early-career investigators in oncology: an EORTC survey-based study Open
Background: The increasing complexity of cancer research presents significant challenges for early-career oncologists in establishing independent research careers. Although dedicated support platforms have emerged in recent years, a thorou…
View article: Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset Open
View article: 496P Fertility preservation practices at gastrointestinal (GI) oncology in Europe: A Pan-European study
496P Fertility preservation practices at gastrointestinal (GI) oncology in Europe: A Pan-European study Open
View article: Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis
Barriers and Facilitators in Diagnostic Pathways That Align Universal Tumor Screening and Mainstream Genetic Testing for Lynch Syndrome in Colorectal Cancer: Protocol for a Scoping Review With a Narrative Synthesis Open
Background Approximately 3% of colorectal cancers (CRCs) are due to Lynch syndrome (LS), a hereditary cancer syndrome caused by pathogenic variants (PVs) in the mismatch repair (MMR) genes. Patients with CRC and LS have elevated lifetime r…
View article: Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) Open
Objective Patient-reported outcomes (PROs) are considered the gold standard for the assessment of subjective symptoms, quality of life (QoL) and patient well-being in both clinical trials and clinical practice. Here, we report key discussi…
View article: Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial Open
View article: Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study Open
In asymptomatic mEGC, immediate start of treatment is preferred by European experts. Consensus was established that treatment can be deferred for patients who prefer deferral and either have a pre-existent WHO/ECOG performance status of 2 …
View article: Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i><sup><i>V600E</i></sup>-mutated metastatic colorectal cancer treated with targeted therapy
Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i><sup><i>V600E</i></sup>-mutated metastatic colorectal cancer treated with targeted therapy Open
Background: Encorafenib plus cetuximab (EC) is the standard of care for pre-treated BRAF V600E mutated metastatic colorectal cancer (mCRC). Depth of response (DpR) and early tumour shrinkage (ETS) previously showed a strong correlation wit…
View article: Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study Open
View article: Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer
Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer Open
Background: Patients with metastatic colorectal cancer (mCRC) carrying a deficit in the mismatch repair system/microsatellite instability (dMMR/MSI) show great responses to immune checkpoint inhibitors. However, 30% of patients with dMMR/M…
View article: 129P Clinical and molecular landscape of deficient mismatch repair (dMMR) colon cancer (CC) patients: Data from a large consecutive single-center cohort
129P Clinical and molecular landscape of deficient mismatch repair (dMMR) colon cancer (CC) patients: Data from a large consecutive single-center cohort Open
View article: Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort Open
Background Comprehensive next-generation sequencing is widely used for precision oncology and precision prevention approaches. We aimed to determine the yield of actionable gene variants, the capacity to uncover hereditary predisposition a…
View article: Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset Open
Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC. Among patients with pMMR/MSS tumors, combinatory chemotherapy ± anti-VEGF appears t…
View article: Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?
Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Open
Fruquintinib is a valid therapeutic option for heavily pretreated mCRC patients. However, an optimal sequence of treatments is yet to be defined. In this review, we propose an algorithm for later lines of treatment to integrate fruquintini…
View article: ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients
ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients Open
Background: International guidelines recommend universal screening for Lynch syndrome (LS) through somatic DNA mismatch repair deficiency (dMMR) testing in all colorectal cancers (CRCs). However, LS remains largely underdiagnosed. Mainstre…
View article: Lynch Syndrome: From Multidisciplinary Management to Precision Prevention
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention Open
Background and Aims: Lynch syndrome (LS) is currently one of the most prevalent hereditary cancer conditions, accounting for 3% of all colorectal cancers and for up to 15% of those with DNA mismatch repair (MMR) deficiency, and it was one …
View article: Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting
Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting Open
View article: BRAF<sup>V600E</sup> immunohistochemistry can reliably substitute <i>BRAF</i> molecular testing in the Lynch syndrome screening algorithm in colorectal cancer
BRAF<sup>V600E</sup> immunohistochemistry can reliably substitute <i>BRAF</i> molecular testing in the Lynch syndrome screening algorithm in colorectal cancer Open
Aims The Lynch syndrome (LS) screening algorithm requires BRAF testing as a fundamental step to distinguish sporadic from LS‐associated colorectal carcinomas (CRC). BRAF testing by immunohistochemistry (IHC) has shown variable results in t…
View article: Clinical and Molecular Landscape of Mismatch Repair Deficient (Dmmr) Colon Cancer (Cc) Patients: Data from a Large Consecutive Single-Center Cohort
Clinical and Molecular Landscape of Mismatch Repair Deficient (Dmmr) Colon Cancer (Cc) Patients: Data from a Large Consecutive Single-Center Cohort Open
View article: Clinical and Molecular Landscape of Mismatch Repair Deficient (Dmmr) Colon Cancer (Cc) Patients: Data from a Large Consecutive Single-Center Cohort
Clinical and Molecular Landscape of Mismatch Repair Deficient (Dmmr) Colon Cancer (Cc) Patients: Data from a Large Consecutive Single-Center Cohort Open
View article: 1635P Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
1635P Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients Open
View article: 223P Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
223P Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers Open
View article: #412 Pembrolizumab in metastatic cancer patients with microsatellite instability: subgroup analysis on endometrial cancer patients, results from a single center study
#412 Pembrolizumab in metastatic cancer patients with microsatellite instability: subgroup analysis on endometrial cancer patients, results from a single center study Open
Introduction/Background Advanced Endometrial Cancer (EC) has limited therapeutic strategies after failure of first line, with 5-year survival rate of 18%. Approximately 30% of these tumors are microsatellite instability-high (MSI-H) or mis…
View article: Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand?
Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? Open
The therapeutic landscape in locally advanced rectal cancer (LARC) has undergone a significant paradigm shift in recent years with the rising adoption of total neoadjuvant treatment (TNT). This comprehensive approach entails administering …
View article: Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients
Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients Open
EDITORIAL article Front. Oncol., 21 July 2023Sec. Cancer Genetics Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1240963
View article: PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system Open
View article: Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens
Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens Open
View article: P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment Open